Stock


Why Apple (AAPL) Remains a ‘Buy the Dip’ Stock

By Richard Robinson The biggest difference between investors and traders is their holding periods. Traders typically hold a position from between a few …

All Eyes on Nvidia (NVDA) Stock Ahead of FQ319 Earnings

Investors should be prepared for a possible big move in Nvidia (NVDA) stock — either up or down. The graphics giant has been …

Analyst Drops Apple (AAPL) From the Tree; Here’s Why

Apple (AAPL) no longer has the support of Guggenheim analyst Robert Cihra. Cihra downgrades the stock from Buy to Neutral and removed his …

Analyst Stays Upbeat About Amarin (AMRN) Stock While the Rest of the Street Panics

Amarin (AMRN) stock has risen and dipped after varying responses from investors who were tuned into data reports from the biotech’s cardio-vascular REDUCE-It …

Here’s Why Micron (MU) Stock is a Good Buy for the Long Haul

Micron (MU) stock is suffering a bit in the market right now, falling 6% year-to-date. Though the share price rose in 2017 when …

The Bullish Thesis for Roku, Inc. (ROKU) Stock Appears to Be Stronger

By Ophir Gottlieb and Tiernan Ray Top Pick Roku (ROKU) beat earnings estimates for revenue, EPS, active accounts, gross margins, and raised estimates …

Aerie Pharmaceuticals (AERI) Has a New Set of Bullish Eyes on its Stock

Aerie Pharmaceuticals (AERI) has a new bull. Esther Rajavelu of Oppenheimer initiates coverage of the biotech with an Outperform rating and a $64 …

Amarin (AMRN) Stock: This Bullish Analyst Ignores the Recent Negative Noise

Amarin (AMRN) stock is on a nosedive today, falling over 20%, after the Irish biopharma showed updated results from a cardiovascular study called …

Top Analyst Sets Expectations on Nvidia (NVDA) Stock Ahead of Earnings

Even though the semiconductor industry has been on a tear these past few years, some investors are starting to question whether or not …

Catalyst Pharmaceuticals (CPRX): A Biotech Stock This Analyst Is Closely Watching

Every small-cap biotechnology investor knows the industry is prone to binary events. Whether it’s receiving updates from an important clinical trial or hearing …